Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Daiichi Sankyo
Cantor Fitzgerald
Deloitte
Medtronic
Accenture
US Army
Novartis
Johnson and Johnson
Boehringer Ingelheim

Generated: October 20, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 202088

« Back to Dashboard
NDA 202088 describes SUPRENZA, which is a drug marketed by Citius Pharms and is included in one NDA. It is available from one supplier. There are two patents protecting this drug and two Paragraph IV challenges. Additional details are available on the SUPRENZA profile page.

The generic ingredient in SUPRENZA is phentermine hydrochloride. There are seventeen drug master file entries for this compound. Forty-six suppliers are listed for this compound. Additional details are available on the phentermine hydrochloride profile page.

Summary for NDA: 202088

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:2
Formulation / Manufacturing:see details

Pharmacology for NDA: 202088

Suppliers and Packaging for NDA: 202088

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
SUPRENZA
phentermine hydrochloride
TABLET, ORALLY DISINTEGRATING;ORAL 202088 NDA Akrimax Pharmaceuticals, LLC 24090-720 24090-720-77 7 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE, PLASTIC (24090-720-77)
SUPRENZA
phentermine hydrochloride
TABLET, ORALLY DISINTEGRATING;ORAL 202088 NDA Akrimax Pharmaceuticals, LLC 24090-720 24090-720-85 30 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE, PLASTIC (24090-720-85)

Summary for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:TABLET, ORALLY DISINTEGRATING;ORALStrength15MG
Approval Date:Jun 13, 2011TE:RLD:No
Patent:► SubscribePatent Expiration:Jul 23, 2018Product Flag?YSubstance Flag?Delist Request?
Patent:► SubscribePatent Expiration:Mar 14, 2029Product Flag?YSubstance Flag?Delist Request?

Summary for product number 002

Active Rx/OTC/Discontinued:DISCNDosage:TABLET, ORALLY DISINTEGRATING;ORALStrength30MG
Approval Date:Jun 13, 2011TE:RLD:No
Patent:► SubscribePatent Expiration:Jul 23, 2018Product Flag?YSubstance Flag?Delist Request?


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Teva
Deloitte
QuintilesIMS
Dow
Accenture
Queensland Health
US Department of Justice
Citi
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot